Literature DB >> 16854201

Evaluation of potential modifiers of the palatal phenotype in the 22q11.2 deletion syndrome.

Deborah A Driscoll1, Torrey Boland, Beverly S Emanuel, Richard E Kirschner, Don LaRossa, Jeanne Manson, Donna McDonald-McGinn, Peter Randall, Cynthia Solot, Elaine Zackai, Laura E Mitchell.   

Abstract

OBJECTIVE: To evaluate potential modifiers of the palatal phenotype in individuals with the 22q11.2 deletion syndrome.
DESIGN: Data from 356 subjects enrolled in a study of the 22q11.2 deletion syndrome were used to evaluate potential modifiers of the palatal phenotype. Specifically, subjects with and without velopharyngeal inadequacy and/or structural malformations of the palate were compared with respect to gender, race, and genotype for variants of seven genes that may influence palatal development.
METHODS: The chi-square test or Fisher exact test was used to evaluate the association between palatal phenotype and each potential modifier. Odds ratios and their associated 95% confidence intervals were used to measure the magnitude of the association between palatal phenotype, subject gender and race, and each of the bi-allelic variants.
RESULTS: The palatal phenotype observed in individuals with the 22q11.2 deletion syndrome was significantly associated with both gender and race. In addition, there was tentative evidence that the palatal phenotype may be influenced by variation within the gene that encodes methionine synthase.
CONCLUSIONS: Variation in the palatal phenotype observed between individuals with the 22q11.2 deletion syndrome may be related to personal characteristics such as gender and race as well as variation within genes that reside outside of the 22q11.2 region.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854201      PMCID: PMC2818507          DOI: 10.1597/05-070.1

Source DB:  PubMed          Journal:  Cleft Palate Craniofac J        ISSN: 1055-6656


  39 in total

1.  Comorbidity of 5,10-methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms and risk for neural tube defects.

Authors:  G L Johanning; T Tamura; K E Johnston; K D Wenstrom
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 2.  Monozygotic twins with chromosome 22q11 deletion and discordant phenotypes: updates with an epigenetic hypothesis.

Authors:  S M Singh; B Murphy; R O'Reilly
Journal:  J Med Genet       Date:  2002-11       Impact factor: 6.318

3.  Transforming growth factor-alpha (TGFA): genomic structure, boundary sequences, and mutation analysis in nonsyndromic cleft lip/palate and cleft palate only.

Authors:  J Machida; K i Yoshiura; C D Funkhauser; N Natsume; T Kawai; J C Murray
Journal:  Genomics       Date:  1999-11-01       Impact factor: 5.736

4.  Genetic factors are major determinants of phenotypic variability in a mouse model of the DiGeorge/del22q11 syndromes.

Authors:  I Taddei; M Morishima; T Huynh; E A Lindsay
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

5.  Accurate and rapid "multiplex heteroduplexing" method for genotyping key enzymes involved in folate/homocysteine metabolism.

Authors:  S Barbaux; L A Kluijtmans; A S Whitehead
Journal:  Clin Chem       Date:  2000-07       Impact factor: 8.327

6.  Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects.

Authors:  Huiping Zhu; Ned J Wicker; Gary M Shaw; Edward J Lammer; Kate Hendricks; Lucina Suarez; Mark Canfield; Richard H Finnell
Journal:  Mol Genet Metab       Date:  2003-03       Impact factor: 4.797

7.  A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population.

Authors:  Lorenzo D Botto; Kristin May; Paul M Fernhoff; Adolfo Correa; Karlene Coleman; Sonja A Rasmussen; Robert K Merritt; Leslie A O'Leary; Lee-Yang Wong; E Marsha Elixson; William T Mahle; Robert M Campbell
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

8.  VEGF: a modifier of the del22q11 (DiGeorge) syndrome?

Authors:  Ingeborg Stalmans; Diether Lambrechts; Frederik De Smet; Sandra Jansen; Jian Wang; Sunit Maity; Paige Kneer; Maren von der Ohe; Ann Swillen; Christa Maes; Marc Gewillig; Daniel G M Molin; Peter Hellings; Thurid Boetel; Maartin Haardt; Veerle Compernolle; Mieke Dewerchin; Stephane Plaisance; Robert Vlietinck; Beverly Emanuel; Adriana C Gittenberger-de Groot; Peter Scambler; Bernice Morrow; Deborah A Driscol; Lieve Moons; Camila V Esguerra; Geert Carmeliet; Annett Behn-Krappa; Koen Devriendt; Désiré Collen; Simon J Conway; Peter Carmeliet
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

9.  Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population.

Authors:  Patrizia De Marco; Maria Grazia Calevo; Anna Moroni; Lorenza Arata; Elisa Merello; Richard H Finnell; Huiping Zhu; Luciano Andreussi; Armando Cama; Valeria Capra
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

10.  Complete sequencing shows a role for MSX1 in non-syndromic cleft lip and palate.

Authors:  P A Jezewski; A R Vieira; C Nishimura; B Ludwig; M Johnson; S E O'Brien; S Daack-Hirsch; R E Schultz; A Weber; B Nepomucena; P A Romitti; K Christensen; I M Orioli; E E Castilla; J Machida; N Natsume; J C Murray
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

View more
  8 in total

1.  Evaluation of potential modifiers of the cardiac phenotype in the 22q11.2 deletion syndrome.

Authors:  Elizabeth Goldmuntz; Deborah A Driscoll; Beverly S Emanuel; Donna McDonald-McGinn; Minghua Mei; Elaine Zackai; Laura E Mitchell
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-02

Review 2.  Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome.

Authors:  Blaine Crowley; Melanie Ruffner; Donna M McDonald McGinn; Kathleen E Sullivan
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

3.  Biallelic expression of Tbx1 protects the embryo from developmental defects caused by increased receptor tyrosine kinase signaling.

Authors:  Subreena Simrick; Dorota Szumska; Jennifer R Gardiner; Kieran Jones; Karun Sagar; Bernice Morrow; Shoumo Bhattacharya; M Albert Basson
Journal:  Dev Dyn       Date:  2012-06-26       Impact factor: 3.780

4.  Chromosome 22q11.2 microdeletion in monozygotic twins with discordant phenotype and deletion size.

Authors:  Ashutosh Halder; Manish Jain; Isha Chaudhary; Binuja Varma
Journal:  Mol Cytogenet       Date:  2012-03-13       Impact factor: 2.009

5.  Clinical and molecular cytogenetic studies of an unrecognised 22q11.2 deletion in three families.

Authors:  Linhuan Huang; Yingjun Xie; Yi Zhou; Yanmin Luo; Xuan Huang; Zhe Xu; Danlei Cai; Qun Fang
Journal:  Exp Ther Med       Date:  2015-01-21       Impact factor: 2.447

6.  Elevated homocysteine and N-methyl-d-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome.

Authors:  Simon Vann Jones; Subimal Banerjee; A David Smith; Helga Refsum; Belinda Lennox
Journal:  Oxf Med Case Reports       Date:  2017-12-29

7.  Characteristic face: a key indicator for direct diagnosis of 22q11.2 deletions in Chinese velocardiofacial syndrome patients.

Authors:  Dandan Wu; Yang Chen; Chen Xu; Ke Wang; Huijun Wang; Fengyun Zheng; Duan Ma; Guomin Wang
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

8.  Candidate modifier genes for immune function in 22q11.2 deletion syndrome.

Authors:  Catherina T Pinnaro; Travis Henry; Heather J Major; Mrutyunjaya Parida; Lucy E DesJardin; John R Manak; Benjamin W Darbro
Journal:  Mol Genet Genomic Med       Date:  2019-12-12       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.